Antibody‐drug conjugate MORAb‐202 exhibits long‐lasting antitumor efficacy in TNBC PDx models

Trastuzumab Deruxtecan: First Approval

(2020) Susan J. Keam   DRUGS

Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

(2020) David M. Goldenberg et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

(2019) Nicholas C. Richardson et al.   ONCOLOGIST

Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance

(2019) Micol Eleonora Fiori et al.   Molecular Cancer

Polatuzumab Vedotin: First Global Approval

(2019) Emma D. Deeks   DRUGS

Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies

(2019) Tom J. Harryvan et al.   Journal of Clinical Medicine

Antibodies to watch in 2020

(2019) Hélène Kaplon et al.   mAbs

Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies

(2018) Alice Lee et al.   CANCER TREATMENT REVIEWS

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment

(2018) Shinichiro Kashiwagi et al.   Journal of Translational Medicine

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia

(2018) Kelly J. Norsworthy et al.   ONCOLOGIST

MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity

(2018) Xin Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

(2017) Joanna C. Masters et al.   INVESTIGATIONAL NEW DRUGS

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine

(2017) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

(2016) X. Pivot et al.   ANNALS OF ONCOLOGY

Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?

(2016) Hans-Peter Gerber et al.   BIOCHEMICAL PHARMACOLOGY

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab

(2016) Shigeto Ueda et al.   BRITISH JOURNAL OF CANCER

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Eribulin — a welcomed advance

(2016) Diana Romero   Nature Reviews Clinical Oncology

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

(2016) Fabrizio Marcucci et al.   NATURE REVIEWS DRUG DISCOVERY

FDA Approves Eribulin for Advanced Liposarcoma

(2016)   Cancer Discovery

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial

(2015) Robert J. Morgan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression

(2015) Akira Kurosaki et al.   INTERNATIONAL JOURNAL OF CANCER

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2015) Peter A. Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

An FDA oncology analysis of antibody-drug conjugates

(2015) Haleh Saber et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade

(2015) Philipp Müller et al.   Science Translational Medicine

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors

(2015) Brian M. Necela et al.   PLoS One

Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes

(2015) Daniel J. O’Shannessy et al.   Oncotarget

Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance

(2015) Daniel J. O'Shannessy et al.   Oncotarget

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

(2014) Yasuhiro Funahashi et al.   CANCER SCIENCE

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

(2014) Yasutsuna Sasaki et al.   INVESTIGATIONAL NEW DRUGS

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

(2014) Parvin F. Peddi et al.   Therapeutic Advances in Medical Oncology

Folate Receptor α Associated With Triple-Negative Breast Cancer and Poor Prognosis

(2013) Zhang Zhang et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Brentuximab vedotin

(2012) Niels W. C.J. van de Donk et al.   mAbs

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor  , in Epithelial Ovarian Cancer: a Phase I Study

(2010) J. A. Konner et al.   CLINICAL CANCER RESEARCH

Folate receptor alpha as a tumor target in epithelial ovarian cancer

(2008) Kimberly R. Kalli et al.   GYNECOLOGIC ONCOLOGY